Reimbursed Care Access in French Guiana

Currently classified as a strictly controlled substance under French national drug scheduling (hallucinogenic mushrooms and their active principles are treated as narcotics), with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. (French law treats MDMA as a narcotic; clinical trials may be authorised under standard research frameworks.) #

Esketamine (marketed as SPRAVATO) is an authorised medicinal product in France and subject to assessment and recommendations by the Haute Autorité de Santé (HAS); HAS has published opinions and reimbursement decisions relating to SPRAVATO for treatment of major depressive episodes in specific, severe cases, and national marketing authorisation/coverage decisions made for metropolitan France apply to French Guiana as part of the French Republic's territory. #

Regulatory body and framework: SPRAVATO is evaluated and monitored by the HAS (Haute Autorité de Santé) which issues opinions on clinical benefit and reimbursement (inscription/remboursement) under the French social security system. The product is distributed and prescribed under the same national regulatory framework that covers all French departments, including overseas departments such as French Guiana. #

Public vs private insurance and reimbursement: When HAS issues a positive opinion for reimbursement/inscription, the product becomes eligible for partial or full reimbursement under the régime général (French social security) and associated complementary assurances, subject to the specific HAS wording and the national tariff/CIP coding and pricing decisions. Local hospital and clinic implementation in French Guiana follows the same national reimbursement rules; however, practical access can be limited by availability of services (specialist centres authorized to administer and monitor esketamine) and supply logistics in overseas territories. #

Indications and clinical prerequisites: HAS guidance ties esketamine use to adult patients with severe or treatment‑resistant depression in combination with an oral antidepressant and subject to risk minimisation measures, in line with the product's approved indication and the national summary of product characteristics. Prescribing is restricted to appropriate specialist settings with monitoring for acute adverse events. Exact patient‑selection criteria, monitoring requirements and reimbursement scope are specified in HAS opinions and the product's marketing authorisation. #

Used off‑label in some European specialist settings (including France) for treatment‑resistant depression and other refractory conditions, but not widely integrated into standard reimbursed pathways — access in French Guiana follows the same constraints as in metropolitan France (restricted to specialist centres, case‑by‑case hospital protocols, and typically without guaranteed routine reimbursement by public insurance for off‑label indications). #

Regulatory and payer nuance: Ketamine (racemic ketamine) is a legally recognised medicinal product when used for approved anaesthetic/analgesic indications; these authorised uses are reimbursed when provided in standard hospital/ambulatory care settings. For psychiatric indications (e.g., intravenous ketamine for TRD), the use is off‑label, and French public health insurance generally controls off‑label use tightly — reimbursement requires hospital or regional protocols, multidisciplinary oversight, and often individual case justification. Clinical practice guidance in Europe emphasises restriction to severe, refractory cases and specialist oversight. #

Regional implementation: Because French Guiana is administratively part of France, national rules about off‑label prescribing and reimbursement apply; however, actual availability depends on whether local hospitals/clinics have established specialist programmes to deliver monitored ketamine treatments. Patients may therefore need referral to metropolitan centres or specialised units and private payment arrangements when local public provision is not available.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. French law treats DMT and plant sources as narcotics; possession, manufacture or use is prohibited except within authorised research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. (As with other powerful tryptamines, France treats these substances as narcotics; access is limited to approved clinical trials or authorised research.) #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no established, reimbursed medical pathway for ibogaine in France/French Guiana. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Historical French jurisprudence that once permitted certain religious uses was followed by scheduling of the relevant plant alkaloids; possession and use are effectively illegal under the French narcotics framework. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline and mescaline‑containing cacti are controlled under French narcotics law; exceptions only exist within tightly regulated research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The broad family of phenethylamine psychedelics (2C‑series) are treated as narcotics or controlled psychoactive substances in France. #